The Cigna Group
CI: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$368.00 | Rymdk | Kdzjqsbsy |
Cigna Earnings: Solid Trends Boost Outlook and Fair Value, Despite Regulatory Scrutiny on PBM
Narrow-moat Cigna turned in solid first-quarter results, and the firm mildly increased its 2023 outlook. Considering these solid trends and cash flow generated since our last valuation change, we are boosting our fair value estimate 7% to $344 per share. Shares remain moderately undervalued, probably reflecting some of the renewed regulatory risks to its pharmacy benefit management, or PBM, operations. However, we think those risks will be manageable over time.